Moclobemide


Reversible MAO-A inhibitor (RIMA)

A morpholine benzamide reversible inhibitor of MAO-A (RIMA); the first MAOI that does not require dietary tyramine restriction.

Abstract

Moclobemide (4-chloro-N-(2-morpholin-4-ylethyl)benzamide; CAS 71320-77-9; molecular formula C13H17ClN2O2; molecular weight 268.74) is a morpholine benzamide reversible inhibitor of MAO-A (RIMA) developed at Roche and approved in Europe (1989) and Canada (1992) under the trade name Aurorix; never FDA approved for the US market. MAO-A selectivity ratio is approximately 100:1 over MAO-B at low doses. Plasma half-life is 1 to 4 hours; the short half-life dictates twice-daily dosing. Hepatic metabolism via CYP2C19 is the primary clearance pathway. Approved for major depressive disorder and social anxiety disorder. The eliminated tyramine restriction has not produced the expected clinical takeoff: efficacy is modestly inferior to TCAs in head-to-head trials, and the drug remains a niche option. Used as the canonical RIMA in mechanism studies.

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.


Browse all monographs

Previous monograph
Next monograph